Cns Pharmaceuticals, INC 8-K filings

CNS Pharmaceuticals announces a strategic pivot towards oncology and neurology, bolstered by a $22.5 million financing round and a new executive team.

CNS Pharmaceuticals, Inc. announced a $22.5 million private placement of common stock and pre-funded warrants to institutional investors.

CNS Pharmaceuticals, Inc. announced the appointment of Dr. Lynne Kelley as its new Chief Medical Officer, effective March 2, 2026, following the separation of Dr. Sandra Silberman.

CNS Pharmaceuticals, Inc. announced the appointment of Steve OLoughlin as its new Chief Financial Officer, effective March 2, 2026, with current CFO Christopher Downs transitioning to Senior Vice President Finance.

CNS Pharmaceuticals, Inc. announced the appointment of Rami Levin as its new Chief Executive Officer and President, effective January 1, 2026, following the resignation of John Climaco.

CNS Pharmaceuticals' stockholders approved a significant increase in authorized common and preferred shares and expanded its 2020 Equity Plan.

CNS Pharmaceuticals, Inc. has enacted a 1-for-12 reverse stock split to consolidate its common shares and adjust its capital structure, effective July 22, 2025, primarily to maintain its NASDAQ listing.

CNS Pharmaceuticals, Inc. announced a strategic shift in its oncology pipeline, prioritizing the blood-brain barrier permeable drug candidate TPI 287 for Glioblastoma Multiforme after its Berubicin monotherapy trial did not achieve statistical significance in overall survival.

CNS Pharmaceuticals has entered into a placement agency agreement for a public offering of common stock, pre-funded warrants, and Series F warrants, aiming to raise approximately $5.0 million before expenses.

CNS Pharmaceuticals is focusing on advancing its lead drug candidate, TPI 287, for the treatment of Glioblastoma Multiforme (GBM) and exploring strategic options for Berubicin following primary analysis results.

CNS Pharmaceuticals (CNSP) has regained compliance with Nasdaq's minimum bid price rule, but will be subject to a one-year monitoring period.

CNS Pharmaceuticals has increased its share sales agreement with A.G.P./Alliance Global Partners to $43.5 million, including funds remaining from a previous agreement.

CNS Pharmaceuticals implements a 1-for-50 reverse stock split to boost its share price and meet Nasdaq's minimum listing requirements.

CNS Pharmaceuticals is advancing its brain cancer therapies, with primary analysis for Berubicin expected in the first half of 2025 and plans to initiate a registration study for TPI 287.

CNS Pharmaceuticals highlighted the progress of its clinical programs, including the fully enrolled pivotal trial for Berubicin and the advancement of TPI 287, at its virtual analyst and investor day.

CNS Pharmaceuticals' stockholders have approved a reverse stock split authorization and the repricing of warrants at a special meeting held on November 26, 2024.

CNS Pharmaceuticals has been granted a temporary exception by a Nasdaq Hearings Panel to regain compliance with the minimum bid price requirement until March 11, 2025.

CNS Pharmaceuticals, Inc. has announced a $3 million registered direct offering of common stock, priced at-the-market under Nasdaq rules.

CNS Pharmaceuticals is at risk of being delisted from the Nasdaq Capital Market after its stock price failed to maintain the minimum bid price of $1.00 per share for 30 consecutive business days.

CNS Pharmaceuticals has received a delisting notice from Nasdaq due to its stock price falling below $1.00 per share for 30 consecutive days and is ineligible for a standard compliance period due to prior reverse stock splits.

CNS Pharmaceuticals has successfully regained compliance with Nasdaq's minimum stockholders' equity requirement, averting a potential delisting.

CNS Pharmaceuticals has regained compliance with Nasdaq's minimum stockholders' equity requirement following the sale of shares, securing its continued listing.

CNS Pharmaceuticals has increased the potential value of its share offering through A.G.P./Alliance Global Partners to $25 million, in addition to the original $5.2 million, bringing the total available under the ATM program to $30.2 million.

CNS Pharmaceuticals has secured an exclusive license for TPI 287, a novel drug candidate for brain malignancies, complementing its ongoing Berubicin program, and has launched a new corporate brand.

CNS Pharmaceuticals has entered into a sales agreement for up to $5.2 million in common stock and amended certain warrants to facilitate at-the-market offerings.

CNS Pharmaceuticals has received a final extension until August 12, 2024, to meet Nasdaq's minimum stockholders' equity requirement and avoid delisting.

CNS Pharmaceuticals has regained compliance with the Nasdaq's minimum bid price requirement, but still needs to meet the minimum stockholders' equity requirement to avoid delisting.

CNS Pharmaceuticals has successfully regained compliance with Nasdaq's minimum bid price requirement after its stock price closed above $1.00 for 20 consecutive business days.

CNS Pharmaceuticals, Inc. has announced a registered direct offering and concurrent private placement of shares and warrants to healthcare-focused institutional investors for gross proceeds of approximately $1.98 million.

CNS Pharmaceuticals, Inc. has announced a registered direct offering and concurrent private placement of shares and warrants for gross proceeds of approximately $1.39 million.